Jemperli Shows Promising Interim Results for Advanced Rectal Cancer

GSK has announced encouraging interim analysis results for Jemperli (dostarlimab) in patients with dMMR/MSI-H locally advanced rectal cancer. The data indicate sustained clinical complete responses, with a significant rate of participants showing no detectable signs of cancer over a year after treatment. These findings suggest the potential for dostarlimab to eliminate the need for chemotherapy, radiation, and surgery in some patients, and the data will be submitted for regulatory review.